SARS-CoV-2–host proteome interactions for antiviral drug discovery

SARS-CoV-2–host proteome interactions for antiviral drug discovery

Treatment options for COVID-19, caused by SARS-CoV-2, remain limited. Understanding viral pathogenesis at the molecular level is critical to develop effective therapy. Some recent studies have explored SARS-CoV-2–host interactomes and provided great resources for understanding viral replication. How...

Full description

Bibliographic Details
Main Authors: Bogacheva, M. (Author), Gawriyski, L. (Author), Hassinen, A. (Author), Huuskonen, S. (Author), Keskitalo, S. (Author), Laitinen, T. (Author), Liu, X. (Author), Öhman, T. (Author), Pietiäinen, V. (Author), Pöhner, I. (Author), Poso, A. (Author), Redchuk, T. (Author), Salokas, K. (Author), Tonduru, A.K (Author), Varjosalo, M. (Author), Vartiainen, M.K (Author)
Format: Article
Language:English
Published: John Wiley and Sons Inc 2021
Subjects:
Antiviral Agents
antivirus agent
COVID-19
drug development
drug discovery
Drug Discovery
drug effect
drug repositioning
Drug Repositioning
drug therapy
host pathogen interaction
Host-Pathogen Interactions
human
Humans
mass spectrometry
Mass Spectrometry
methotrexate
Methotrexate
physiology
proteome
Proteome
proteomics
Proteomics
SARS-CoV-2
virology
virus replication
Virus Replication
virus–host interactions
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items